Hellmann Pernille H, Bagger Jonatan I, Carlander Katrine R, Hansen Katrine B, Forman Julie L, Størling Joachim, Chabanova Elizaveta, Holst Jens, Vilsbøll Tina, Knop Filip K
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Endocr Connect. 2023 Mar 28;12(4). doi: 10.1530/EC-22-0334. Print 2023 Apr 1.
Preclinically, curcumin has been shown to protect against glucocorticoid-induced insulin resistance. We evaluated the effect of curcumin administered with prednisolone in healthy overweight or obese men.
In a double-blind, parallel-group trial, 24 overweight/obese non-diabetic men were randomised to one of three intervention groups (A) prednisolone placebo+curcumin placebo, (B) prednisolone (50 mg/day)+curcumin placebo or (C) prednisolone and curcumin (400 mg/day). Curcumin or curcumin placebo treatment started 1 day prior to 10-day prednisolone or prednisolone placebo treatment. The primary endpoint was change in prednisolone-induced insulin resistance assessed by homeostatic model assessment of insulin resistance (HOMA2-IR). Other endpoints included anthropometric measurements, magnetic resonance spectroscopy-assessed hepatic fat content, blood pressure, circulating metabolic markers and continuous glucose monitoring measures.
Baseline characteristics (mean ± s.d): age 44.2 ± 13.7 years, BMI 30.1 ± 3.5 kg/m2, HbAlc 33.3 ± 3.2 mmol/mol, HOMA2-IR 1.10 ± 0.45 and fasting plasma glucose 5.2 ± 0.4 mmol/L. Prednisolone significantly increased HOMA2-IR (estimated treatment difference 0.36 (95% CI 0.16; 0.57)). Co-treatment with curcumin had no effect on HOMA2-IR (estimated treatment difference 0.08 (95% CI -0.13; 0.39)). Prednisolone increased HbAlc, insulin, C-peptide, glucagon, blood pressure, mean interstitial glucose, time spent in hyperglycaemia and glucose variability, but no protective effect of curcumin on any of these measures was observed.
In this double-blind, placebo-controlled parallel-group study involving 24 overweight or obese men randomised to one of three treatment arms, curcumin treatment had no protective effect on prednisolone-induced insulin resistance or other glucometabolic perturbations.
临床前研究表明，姜黄素可预防糖皮质激素诱导的胰岛素抵抗。我们评估了姜黄素与泼尼松龙联合给药对健康超重或肥胖男性的影响。
在一项双盲、平行组试验中，24名超重/肥胖非糖尿病男性被随机分配到三个干预组之一：（A）泼尼松龙安慰剂+姜黄素安慰剂；（B）泼尼松龙（50毫克/天）+姜黄素安慰剂；或（C）泼尼松龙和姜黄素（400毫克/天）。姜黄素或姜黄素安慰剂治疗在10天泼尼松龙或泼尼松龙安慰剂治疗前1天开始。主要终点是通过胰岛素抵抗稳态模型评估（HOMA2-IR）评估的泼尼松龙诱导的胰岛素抵抗变化。其他终点包括人体测量、磁共振波谱评估的肝脏脂肪含量、血压、循环代谢标志物和连续血糖监测指标。
基线特征（均值±标准差）：年龄44.2±13.7岁，体重指数30.1±3.5千克/平方米，糖化血红蛋白33.3±3.2毫摩尔/摩尔，HOMA2-IR 1.10±0.45，空腹血糖5.2±0.4毫摩尔/升。泼尼松龙显著增加HOMA2-IR（估计治疗差异0.36（95%置信区间0.16；0.57））。与姜黄素联合治疗对HOMA2-IR无影响（估计治疗差异0.08（95%置信区间-0.13；0.39））。泼尼松龙增加了糖化血红蛋白、胰岛素、C肽、胰高血糖素、血压、平均组织间葡萄糖、高血糖持续时间和血糖变异性，但未观察到姜黄素对这些指标的任何保护作用。
在这项双盲、安慰剂对照的平行组研究中，24名超重或肥胖男性被随机分配到三个治疗组之一，姜黄素治疗对泼尼松龙诱导的胰岛素抵抗或其他糖代谢紊乱无保护作用。
